AQP2 and chronic kidney disease: In patients with CKD G4, the levels of uEV‐AQP1 and ‐AQP2 were also significantly decreased to 23.5% (IQR 20%, 24%) and to 34.2% (IQR 6.2%, 51.2%), respectively, but no significant change for uEV‐TSG101 (81.3%, IQR, 35.5%, 227.7%) was observed.